Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs and Over-the-counter-Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semi-Solid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies and Others), and Therapeutic Class (Anti-Glaucoma, Anti-infection, Anti-inflammation, Anti-allergy, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027

pa_user-types

Check Today's Best Price

$3700 Buy Now
The global ophthalmic drugs market was capitalized for USD 34,772.81 Million in 2019 and is estimated to reach USD 53,365.36 Million by the end of 2027, developing at a CAGR of over 5.5% during the forecast period 2019–2025.
  • Introduction

    Ophthalmic drugs are treatment method to treat eye disease such as cataract, diabetic retinopathy, glaucoma, and other ophthalmic disorders. Factors such as advent of novel ocular drug increasing prevalence of eye disorders especially among older population, increasing investment by market players in the treatment. However, adverse effects associated with ophthalmic drugs unaffordability for ocular surgeries in many emerging countries is hampering the market growth to an extent. The global ophthalmic drugs market was capitalized for USD 34,772.81 Million in 2019 and is estimated to reach USD 53,365.36 Million by the end of 2027, developing at a CAGR of over 5.5% during the forecast period 2019–2025.

    Market Dynamics

    Driver

    • Increasing Disease Prevalence and Strong Developmental Pipeline.
    • Advancements In Drug Delivery and Promising Investment Scenario.

    Restrain

    • Side effects of drugs and longer timeline required for the formulation of ophthalmic drugs
    • Stringent rules and regulation

    Opportunities

    • Increasing demand from emerging market
    • Increase in research and developments by major key players

    Challenges

    • High prices of drugs

    Market Segmentation

    Based on drug class in the ophthalmic drugs market it is segmented into Anti-Allergy, Anti-Vegf Agents, Anti-Inflammatory, Antiglaucoma, and others. Anti-Vegf Agents segment dominated the market growth in the drug class segment in 2020 year, owing to factors such as increasing number of novel drug treatment for ophthalmic drugs. Based on disease type ophthalmic drugs has been segmented into dry eye, eye allergies, retinal disorders, glaucoma and others. Retinal disorder segment dominated the market in the year 2020, due to rising incidence of retinal disease globally.Based on dosage form, dosage form is segmented into eye drops, gel, eye solution, capsule and tablets and others. Eye drops segment dominated the market growth in the year 2020. The market growth can be attributed to the rising usage of eye drops due to its increasing sales volume. Based on the ROA ophthalmic drugs market, it is classified into Topical, Intravitreal, systemic, others. Topical ROA segment dominated the market growth in the year 2020. Based on product type, it is classified into OTC and Prescription drugs. OTC drugs held the largest share in the year 2020, due to the rising number of OTC drugs and the sales volume.

    Regional Analysis

    On the regional basis, the Ophthalmic drugs market has been divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America has been classified into the U.S. and Canada. Europe region has been divided into the UK, Italy, France, Germany, and the Rest of Europe. Asia-Pacific region has been bifurcated into, Japan, India, South Korea, China, and Rest of Asia-Pacific. In addition, the South America region has been segmented into Argentina, Brazil, Mexico, and the Rest of South America. The Middle East & Africa has been divided into GCC Countries, Africa, and the Rest of the Middle East.

    Competitive Landscape

    The major players in the ophthalmic drugs market are Johnson & Johnson Services, Inc., Bausch Health, Allergan, Pfizer, Inc., Bayer AG, Santen Pharmaceutical Co. Ltd., Genentech, Inc., Novartis AG, Regeneron, Merck & Co., Shire plc. and others. Companies are involved into collaborative agreement, expansion, acquisition and product launch to mark their presence in the market.

    Key Segments

    Drug Class

    • Anti-Allergy
    • Anti-Vegf Agents
    • Anti-Inflammatory
    • Antiglaucoma
    • Others

    Disease

    • Dry Eye
    • Eye Allergy
    • Glaucoma
    • Eye Infection
    • Retinal disorders
    • Others

    By Dosage Form

    • Gel
    • Eye solution
    • Capsule
    • Tablets
    • Others

    By Route of Administration

    • Topical
    • Intravitreal
    • Others

    By Product Type

    • OTC
    • Prescription

    By region:

    • North America
      • The U.S.
      • Canada
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Southeast Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa

    Report Scope

    Report Attribute Details
    Market size value in 2021 USD 39.0 billion
    Market size value in 2028 USD 60.3 billion
    Growth Rate CAGR of 6.4% from 2021 to 2028
    Base year for estimation 2020
    Forecast period 2021 – 2028
    Segments covered Type, Application
    Geographies covered North America, Europe, APAC, Latin America and MEA
    Companies Covered Johnson & Johnson Services, Inc., Bausch Health, Allergan, Pfizer, Inc., Bayer AG, Santen Pharmaceutical Co. Ltd., Genentech, Inc., Novartis AG, Regeneron, Merck & Co., Shire plc. And others.

     Key Benefits for the Ophthalmic Drugs Market

    • Our research reports help you understand the consumer behavior and hence assist you to understand the ongoing trend in the market.
    • Our reports give you a 360 degree view of the market assisting you to understand the exact factors that are driving the sales and the possible future changes in consumer tastes. It therefore helps you take informed business decisions.
    • We track the markets right from the research stage and thus offer highly information research findings
    • Our study is based on analysis by in-house team of analysts as well as data gathered by on-field consultants. We use proven survey methodology to find out the actual trends prevailing in the market. We also study and let you understand the factors behind the trending products, applications, technologies etc.
    • Our study reveals you the potential products that may gain traction in next 6 to 8 years. Staying informed of lucrative business opportunities help you stay prepared for the growth in demand for a product in near future.

    Frequently Asked Questions (FAQ):

    What is the size of the global Ophthalmic Drugs market?

    –The size of the global Ophthalmic Drugs market in 2019 was $17.45 billion.

    Who are the major companies operating in the global Ophthalmic Drugs market?

    – Prominent companies include Johnson & Johnson Services, Inc., Bausch Health, Allergan, Pfizer, Inc., Bayer AG, Santen Pharmaceutical Co. Ltd., Genentech, Inc., Novartis AG, Regeneron, Merck & Co., Shire plc. And others..

    What are the major countries in the Europe Ophthalmic Drugs market?

    -The UK, France, Italy, and Germany are key countries for Ophthalmic Drugs in the European region

    keyboard_arrow_up
  • Table of Contents

    Chapter 1. Introduction
    1.1. Report description
    1.2. Key market segments
    1.3. Regional Scope
    1.4. Executive Summary

    Chapter 2. Research Methodology
    2.1. Secondary Research
    2.2. Primary Research
    2.3. Secondary Analyst Tools and Models

    Chapter 3. Market Dynamics
    3.1. Market driver analysis
    3.1.1. Increase in prevalence of ophthalmic disorders
    3.1.2. Advancements in research and development in optometry
    3.1.3. Growth in geriatric population
    3.1.4. Increase in demand for the ophthalmic drugs
    3.2. Market restraint analysis
    3.2.1. Risks associated with ophthalmic drugs
    3.2.2. Longer timeline required for the formulation of ophthalmic drugs
    3.3. Market Opportunity
    3.3.1. Increase in research and developments by major key players
    3.4. Impact analysis
    3.4.1. Impact analysis of COVID-19 on the Ophthalmic Drug market

    Chapter 4. Market Variables and Outlook
    4.1. SWOT Analysis
    4.1.1. Strengths
    4.1.2. Weaknesses
    4.1.3. Opportunities
    4.1.4. Threats
    4.2. Supply Chain Analysis
    4.3. PESTEL Analysis
    4.3.1. Political Landscape
    4.3.2. Economic Landscape
    4.3.3. Social Landscape
    4.3.4. Technological Landscape
    4.3.5. Environmental Landscape
    4.3.6. Legal Landscape
    4.4. Porter’s Five Forces Analysis
    4.4.1. Bargaining Power of Suppliers
    4.4.2. Bargaining Power of Buyers
    4.4.3. Threat of Substitute
    4.4.4. Threat of New Entrant
    4.4.5. Competitive Rivalry

    Chapter 5. Ophthalmic Drugs Market: Indication Estimates & Trend Analysis
    5.1. Ophthalmic Drugs Market value share and forecast, (2015 to 2027)
    5.2. Incremental Growth Analysis and Infographic Presentation
    5.2.1. Dry Eye
    5.2.1.1. Market Size & Forecast, 2019-2026
    5.2.2. Glaucoma
    5.2.2.1. Market Size & Forecast, 2019-2026
    5.2.3. Infection/Inflammation/Allergy
    5.2.3.1. Market Size & Forecast, 2019-2026
    5.2.4. Retinal Disorders
    5.2.4.1. Market Size & Forecast, 2019-2026
    5.2.5. Others
    5.2.5.1. Market Size & Forecast, 2019-2026

    Chapter 6. Ophthalmic Drugs Market: Type Estimates & Trend Analysis
    6.1. Ophthalmic Drugs Market value share and forecast, (2015 to 2027)
    6.2. Incremental Growth Analysis and Infographic Presentation
    6.2.1. Prescription Drugs
    6.2.1.1. Market Size & Forecast, 2019-2026
    6.2.2. Over-the-counter-Drugs
    6.2.2.1. Market Size & Forecast, 2019-2026

    Chapter 7. Ophthalmic Drugs Market: Dosage Form Estimates & Trend Analysis
    7.1. Ophthalmic Drugs Market value share and forecast, (2015 to 2027)
    7.2. Incremental Growth Analysis and Infographic Presentation
    7.2.1. Liquid Ophthalmic Drug Forms
    7.2.1.1. Market Size & Forecast, 2019-2026
    7.2.2. Solid Ophthalmic Drug Forms
    7.2.2.1. Market Size & Forecast, 2019-2026
    7.2.3. Semi-Solid Ophthalmic Drug Forms
    7.2.3.1. Market Size & Forecast, 2019-2026
    7.2.4. Multicompartment Drug Delivery Systems
    7.2.4.1. Market Size & Forecast, 2019-2026
    7.2.5. Other Ophthalmic Drug Forms
    7.2.5.1. Market Size & Forecast, 2019-2026

    Chapter 8. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis
    8.1. Ophthalmic Drugs Market value share and forecast, (2015 to 2027)
    8.2. Incremental Growth Analysis and Infographic Presentation
    8.3. North America
    8.3.1.1. Market Size & Forecast, 2019-2026
    8.4. Europe
    8.4.1.1. Market Size & Forecast, 2019-2026
    8.5. Asia Pacific
    8.5.1.1. Market Size & Forecast, 2019-2026
    8.6. Central & South America
    8.6.1.1. Market Size & Forecast, 2019-2026
    8.7. Middle East & Africa (MEA)
    8.7.1.1. Market Size & Forecast, 2019-2026

    Chapter 9. Ophthalmic Drugs Market: Country Estimates & Trend Analysis
    9.1. Ophthalmic Drugs Market value share and forecast, (2015 to 2027)
    9.2. Incremental Growth Analysis and Infographic Presentation
    9.3. U.S.
    9.3.1.1. Market Size & Forecast, 2019-2026
    9.4. Canada
    9.4.1.1. Market Size & Forecast, 2019-2026
    9.5. Mexico
    9.5.1.1. Market Size & Forecast, 2019-2026
    9.6. UK
    9.6.1.1. Market Size & Forecast, 2019-2026
    9.7. France
    9.7.1.1. Market Size & Forecast, 2019-2026
    9.8. Germany
    9.8.1.1. Market Size & Forecast, 2019-2026
    9.9. Russia
    9.9.1.1. Market Size & Forecast, 2019-2026
    9.10. Italy
    9.10.1.1. Market Size & Forecast, 2019-2026
    9.11. Spain
    9.11.1.1. Market Size & Forecast, 2019-2026
    9.12. China
    9.12.1.1. Market Size & Forecast, 2019-2026
    9.13. India
    9.13.1.1. Market Size & Forecast, 2019-2026
    9.14. Japan
    9.14.1.1. Market Size & Forecast, 2019-2026
    9.15. Indonesia
    9.15.1.1. Market Size & Forecast, 2019-2026
    9.16. South Korea
    9.16.1.1. Market Size & Forecast, 2019-2026
    9.17. Australia
    9.17.1.1. Market Size & Forecast, 2019-2026
    9.18. Brazil
    9.18.1.1. Market Size & Forecast, 2019-2026
    9.19. Argentina
    9.19.1.1. Market Size & Forecast, 2019-2026
    9.20. Saudi Arabia
    9.20.1.1. Market Size & Forecast, 2019-2026
    9.21. UAE
    9.21.1.1. Market Size & Forecast, 2019-2026
    9.22. South Africa
    9.22.1.1. Market Size & Forecast, 2019-2026

    Chapter 10. Competitive Landscape
    10.1. Company Market Share Analysis
    10.2. Vendor Landscape
    10.3. Competition Dashboard

    Chapter 11. Company Profiles
    11.1. Business Overview, Product Landscape, Ffinancial Performance and Company Strategies for below companies
    11.1.1. Johnson & Johnson Services, Inc.
    11.1.1.1. Company Overview
    11.1.1.2. Financial Performance
    11.1.1.3. Product Benchmarking
    11.1.1.4. Geographic Footprint
    11.1.1.5. Strategic Initiatives
    11.1.2. Bausch Health
    11.1.2.1. Company Overview
    11.1.2.2. Financial Performance
    11.1.2.3. Product Benchmarking
    11.1.2.4. Geographic Footprint
    11.1.2.5. Strategic Initiatives
    11.1.3. Allergan
    11.1.3.1. Company Overview
    11.1.3.2. Financial Performance
    11.1.3.3. Product Benchmarking
    11.1.3.4. Geographic Footprint
    11.1.3.5. Strategic Initiatives
    11.1.4. Pfizer, Inc.
    11.1.4.1. Company Overview
    11.1.4.2. Financial Performance
    11.1.4.3. Product Benchmarking
    11.1.4.4. Geographic Footprint
    11.1.4.5. Strategic Initiatives
    11.1.5. Bayer AG
    11.1.5.1. Company Overview
    11.1.5.2. Financial Performance
    11.1.5.3. Product Benchmarking
    11.1.5.4. Geographic Footprint
    11.1.5.5. Strategic Initiatives
    11.1.6. Santen Pharmaceutical Co. Ltd.
    11.1.6.1. Company Overview
    11.1.6.2. Financial Performance
    11.1.6.3. Product Benchmarking
    11.1.6.4. Geographic Footprint
    11.1.6.5. Strategic Initiatives
    11.1.7. Genentech, Inc.
    11.1.7.1. Company Overview
    11.1.7.2. Financial Performance
    11.1.7.3. Product Benchmarking
    11.1.7.4. Geographic Footprint
    11.1.7.5. Strategic Initiatives
    11.1.8. Novartis AG
    11.1.8.1. Company Overview
    11.1.8.2. Financial Performance
    11.1.8.3. Product Benchmarking
    11.1.8.4. Geographic Footprint
    11.1.8.5. Strategic Initiatives
    11.1.9. Regeneron
    11.1.9.1. Company Overview
    11.1.9.2. Financial Performance
    11.1.9.3. Product Benchmarking
    11.1.9.4. Geographic Footprint
    11.1.9.5. Strategic Initiatives
    11.1.10. Merck & Co.
    11.1.10.1. Company Overview
    11.1.10.2. Financial Performance
    11.1.10.3. Product Benchmarking
    11.1.10.4. Geographic Footprint
    11.1.10.5. Strategic Initiatives
    11.1.11. Shire plc.
    11.1.11.1. Company Overview
    11.1.11.2. Financial Performance
    11.1.11.3. Product Benchmarking
    11.1.11.4. Geographic Footprint
    11.1.11.5. Strategic Initiatives
    11.1.12. Others

    keyboard_arrow_up
    • Johnson & Johnson Services, Inc.
    • Bausch Health
    • Allergan, Pfizer, Inc.
    • Bayer AG
    • Santen Pharmaceutical Co. Ltd.
    • Genentech, Inc.
    • Novartis AG
    • Regeneron, Merck & Co.
    • Shire plc.
    keyboard_arrow_up


      • Keep your personal detail safe with us. Privacy Policy
        This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Key benefits to buy this report:

    • What are the key market trends?
    • What are the market dynamics?
    • What are the constraints on category growth?
    • What are the category growth drivers?
    • What are the demand-supply shifts?
    • Who are the suppliers in this market?
    • What are the procurement best practices in this market?

    CLIENTS

    SHARE YOUR CART